Pharming Group N.V. PHAR
Set alert
12.23 USD -0.01 -0.10%
At close · Oct 30
12.23 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
12.09 Day range 12.31
9.11 52-week range 21.18
- YTD
- -30.79%
- 1 year
- -6.93%
- Open
- 12.18
- Prev close
- 12.24
- Mkt cap
- 865.62M
- Vol
- 14.05K
- Avg vol
- 24.59K
- EPS
- 0.32
- P/E
- 38.22
- Div yield
- 0.00%
More statistics
- Low
- 12.09
- High
- 12.31
- Forward P/E
- 216.49
- Beta
- 0.09
- Short ratio
- 0.38
- Inst. own
- 0.14%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.57
- 200-d avg
- 15.63
- 1y target
- 34.35
2Y chart
Events in this range
- Mar 14, 2025Rating: Oppenheimer · Outperform → Outperform
- Mar 20, 2025Rating: HC Wainwright & Co. · Buy → Buy
- Mar 21, 2025Rating: HC Wainwright & Co. · Buy → Buy
- Jul 31, 2025Earnings: 0.06; estimate -0.1; surprise 160%
- Nov 6, 2025Earnings: 0.1; estimate 0.05; surprise 100%
- Mar 12, 2026Earnings: 0.07; estimate 0.15; surprise -53.33%
- Mar 13, 2026Rating: Oppenheimer · Outperform → Outperform
- Mar 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Apr 10, 2026Rating: Canaccord Genuity · — → Buy
- May 7, 2026Earnings: -0.07; estimate 0.05; surprise -240%
- Jul 30, 2026Earnings: 0.02; estimate 0.063; surprise -68.25%
Signals (90)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 2026 | 1 day ago |
| RSI: Overbought | Oct 28, 2026 | 3 days ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 3, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| RSI: Oversold | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 23, 2026 | 3 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| RSI: Oversold | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| RSI: Oversold | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 19, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 3, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 9, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 24, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 11, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Nov 6, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 6, 2025 | 11 months ago |
| SMA: Bearish | Oct 24, 2025 | 1 year ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 21, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| RSI: Overbought | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 18, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 15, 2025 | 1 year ago |
| RSI: Overbought | Aug 8, 2025 | 1 year ago |
| RSI: Overbought | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 9, 2025 | 1 year ago |
| SMA: Bullish | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| RSI: Overbought | Jun 4, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| MACD: Sell Signal | May 19, 2025 | 1 year ago |
| RSI: Overbought | May 8, 2025 | 1 year ago |
| SMA: Bearish | Apr 25, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 16, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 19, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Dec 23, 2024 | 1 year ago |
| RSI: Oversold | Nov 22, 2024 | 1 year ago |
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 1.01B
- Trailing P/E
- 74.63
- Forward P/E
- 216.49
- PEG ratio
- 0.00
- Price / sales
- 2.71
- Price / book
- 3.93
- EPS (TTM)
- 0.19
- Beta
- 0.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3.34%
- Revenue (TTM)
- 369.49M
- Revenue growth
- -8.40%
- Free cash flow
- 59.02M
- Total cash
- 170.18M
- Total debt
- 116.20M
- Return on equity
- 5.04%
- Shares outstanding
- 70.63M
- Short % of float
- 0.01%
- 50-day average
- 13.57
- 200-day average
- 15.63
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 34.35 +180.9% upside
Now 12.23
- Target (low)
- 23.40
- Target (mean)
- 34.35
- Target (high)
- 40.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.063.
Financials — quick view
PHAR Revenue — quarterly 117.56M
PHAR Net income — quarterly 22.43M
PHAR EPS — quarterly 0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.10 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.063 | 0.02 | -0.04 | -68.25% |
| May 7, 2026 | Mar 31, 2026 | 0.05 | -0.07 | -0.12 | -240.00% |
| Mar 12, 2026 | Dec 31, 2025 | 0.15 | 0.07 | -0.08 | -53.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.05 | 0.10 | +0.05 | +100.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 10, 2026 | Canaccord Genuity | init | — | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 13, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Mar 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 20, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2025 | Oppenheimer | main | Outperform | Outperform |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- pharming.com
News
- Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
- Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript
- Pharming Group Q3 Earnings Call Highlights
- Pharming Q3 2026 Earnings Call Transcript
- Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
- Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate
- Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
- Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday
- Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
Your note
Sign in to keep a note on PHAR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Silverberg Bernstein Capital Management LLC | 0.06% | 41,547 | 589.14K | Jun 29, 2026 |
| Smartharvest Portfolios, LLC | 0.02% | 10,797 | 153.10K | Mar 30, 2026 |
| Morgan Stanley | 0.02% | 11,489 | 162.91K | Mar 30, 2026 |
| Citadel Advisors Llc | 0.01% | 10,189 | 144.48K | Mar 30, 2026 |
| Knoll Capital Management, LLC | 0.01% | 4,057 | 57.53K | Mar 30, 2026 |
| Nalls Sherbakoff Group, Llc | 0.00% | 870 | 12.34K | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.02% | 12,463 | 176.72K | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.00% | 2,093 | 29.68K | May 30, 2026 |